A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV.

Sanofi SA is conducting a study titled ‘A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.